Analyst
Jefferies
Analyst
Leerink Partners
Equibles does not estimate personal net worth.
Faisal Khurshid is recorded as Analyst at Jefferies and Analyst at Leerink Partners. Faisal Khurshid has spoken on 5 earnings calls and 1 other investor event across 6 companies, most recently for INSMED Inc on August 6, 2026. Those appearances were for INSMED Inc (INSM), Revolution Medicines, Inc. (RVMD), Incyte Corp (INCY), Summit Therapeutics Inc. (SMMT), AbCellera Biologics Inc. (ABCL) and 1 other company. The companies whose calls Faisal Khurshid spoke on are classified in the Healthcare sector.
“I wanted to ask you, I made some comments in the past about the Brinsupri XUS launch sort of pending clarity on MFN. Can we just get an update on your latest views on that and also how the Japan launch plays into that potentially?”
“There's been a lot of investor excitement about PRMT5 combination data generated with your molecule from your partner, Tango.”
“Can you set expectations for the G12D update that you're going to have at ESMO? And can you possibly give us some more perspective on how you think about competitive positioning and how you see your opportunity to differentiate within the class?”
“I wanted to ask on the FDA review for Harmony, have you guys had any interaction with the FDA since having the BLA submitted? And is there anything in the FDA's stance changing on acceptability of PFS and read through of that to Harmony 3?”
“On 6-5, could you speak to us about whether there's a specific benchmark or bar that you would want to see on testosterone reduction in healthy male volunteers?”
Jefferies
Analyst
Source not stated
Leerink Partners
Analyst
Source not stated
INSM
Biotechnology · Healthcare
INCY
Biotechnology · Healthcare
ATYR
Biotechnology · Healthcare
